Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Ascletis Pharma, Inc. ( (HK:1672) ) has provided an update.
Ascletis Pharma has advanced ASC39, an in-house discovered oral small molecule amylin receptor agonist, as a clinical candidate for obesity, highlighting its comparable receptor selectivity and potency to peptide analog eloralintide in cAMP activation assays. The compound showed high selectivity for the human amylin 1 receptor over the calcitonin receptor, supporting its potential as a differentiated small molecule therapy.
In preclinical diet-induced obese rat models, once-daily oral dosing of ASC39 achieved statistically significant placebo-adjusted weight loss similar to eloralintide, while demonstrating pharmacokinetic properties compatible with once-daily oral use in humans. Ascletis plans to file a U.S. IND for ASC39 oral tablets in the third quarter of 2026, signaling a strategic push into the competitive obesity drug market and potentially broadening its future revenue base if clinical development is successful.
The most recent analyst rating on (HK:1672) stock is a Hold with a HK$13.50 price target. To see the full list of analyst forecasts on Ascletis Pharma, Inc. stock, see the HK:1672 Stock Forecast page.
More about Ascletis Pharma, Inc.
Ascletis Pharma Inc., incorporated in the Cayman Islands and listed in Hong Kong, is a biopharmaceutical company focused on discovering and developing innovative therapies. Leveraging its Artificial Intelligence-assisted Structure-Based Drug Discovery technology, it targets metabolic and other major diseases, with a growing emphasis on obesity treatments for global markets.
Average Trading Volume: 2,818,017
Technical Sentiment Signal: Buy
Current Market Cap: HK$15.79B
For detailed information about 1672 stock, go to TipRanks’ Stock Analysis page.